Clinical Report: In Vivo CAR T: A New Route to Treating Autoimmune Disease

Overview

In vivo CAR T-cell therapy enables targeted delivery of CAR T cells directly within the body. This method addresses challenges associated with ex vivo CAR T-cell therapies, including high costs and complex manufacturing processes.

Background

Chimeric antigen receptor (CAR) T-cell therapy has been primarily used for hematologic malignancies, but its application in autoimmune diseases is limited due to operational challenges. CAR T-cell therapy has the potential to target autoreactive B cells in autoimmune conditions.

Data Highlights

No numerical data available in the source material.

Key Findings

• In vivo CAR T-cell therapy could improve safety and efficacy for autoimmune diseases.
• Current ex vivo CAR T-cell therapies face high costs and complex manufacturing processes.
• Technological advancements, such as modified lipid nanoparticles, facilitate targeted in vivo delivery of CAR T cells.
• CAR T-cell therapy has shown potential in treating autoimmune diseases like lupus and multiple sclerosis.
• Recent trials indicate outcomes for in vivo CAR T-cell therapies in multiple myeloma and other conditions.

Clinical Implications

The development of in vivo CAR T-cell therapies may provide a new treatment avenue for patients with autoimmune diseases. Ongoing research and data evaluation are necessary.

Conclusion

In vivo CAR T-cell therapy addresses barriers associated with traditional methods. Continued research and clinical trials are necessary.

Related Resources & Content

1. CRISPR Enables In Vivo CAR T Cell Production, The Medicine Maker, 2026 -- CRISPR Enables In Vivo CAR T Cell Production
2. Early Findings From First Human Study of In Vivo CAR T in Myeloma, The ASCO Post, 2026 -- Early Findings From First Human Study of In Vivo CAR T in Myeloma
3. CAR-T Cell Therapy Explores Applications in Autoimmune Disorders, Bone Marrow Transplantation, 2024 -- CAR-T Cell Therapy Explores Applications in Autoimmune Disorders
4. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial, Nature Medicine, 2025 -- CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial
5. Blood Cancer Journal — Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
6. American College of Rheumatology Guidelines
7. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial | Nature Medicine
8. Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases | Nature Medicine
9. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | New England Journal of Medicine